Related Experiment Video
Updated: May 7, 2025
Optical Sectioning and Visualization of the Intervertebral Disc from Embryonic Development to Degeneration
Published on: July 8, 2021
Identification and Characterisation of Potential Targets for N6-methyladenosine (m6A) Modification during
Jianlin Shen1,2, Qiang Zhang2, Yujian Lan3
1Department of Orthopaedics, Affiliated Hospital of Putian University, 351100 Putian, Fujian, China.
Background:
The mechanism for RNA methylation during disc degeneration is unclear. The aim of this study was to identify N6-methyladenosine (m6A) markers and therapeutic targets for the prevention and treatment of intervertebral disc degeneration (IDD).
Methods:
Methylated RNA immunoprecipitation sequencing (MeRIP-seq) and quantitative reverse transcription PCR (RT-qPCR) were employed to analyze m6A modifications of IDD-related gene expression. Bioinformatics was used to identify enriched gene pathways in IDD. m6A-RIP-qPCR was used to validate potential targets and markers.
Results And Conclusion:
Human IDD samples exhibited a distinct m6A modification pattern that allowed associated genes and pathways to be identified. These genes had functions such as "nuclear factor kappa-B (NF-κB) binding" and "extracellular matrix components", which are crucial for IDD pathogenesis. ANXA2 showed increased m6A modification in IDD, while SLC3A2 and PBX3 showed decreased m6A methylation. The results of this study offer novel insights for the prevention and treatment of IDD.
Insights
This study reveals distinct N6-methyladenosine (m6A) patterns in intervertebral disc degeneration (IDD). These findings identify potential biomarkers and therapeutic targets for preventing and treating IDD.
Area of Science:
- Epigenetics
- Molecular Biology
- Biochemistry
Background:
- The molecular mechanisms underlying RNA methylation in intervertebral disc degeneration (IDD) remain largely unknown.
- Understanding these mechanisms is crucial for developing effective treatments for IDD.
Purpose of the Study:
- To identify N6-methyladenosine (m6A) epigenetic markers associated with IDD.
- To discover potential therapeutic targets for the prevention and treatment of IDD.
Main Methods:
- Utilized methylated RNA immunoprecipitation sequencing (MeRIP-seq) to analyze m6A modifications in IDD.
- Employed quantitative reverse transcription PCR (RT-qPCR) and bioinformatics to identify IDD-related genes and pathways.
- Validated potential targets and markers using m6A-RIP-qPCR.
Main Results:
- Identified a unique m6A modification pattern in human IDD samples.
- Associated genes involved in "nuclear factor kappa-B (NF-κB) binding" and "extracellular matrix components" with IDD pathogenesis.
- Observed increased m6A modification in ANXA2 and decreased m6A methylation in SLC3A2 and PBX3 in IDD.
Conclusions:
- The distinct m6A patterns provide novel insights into IDD pathogenesis.
- Identified specific genes (ANXA2, SLC3A2, PBX3) as potential targets for IDD intervention.
- Offers a foundation for developing targeted therapies for intervertebral disc degeneration.
